1400 SIERRA POINT PARKWAY, BRISBANE, CA
Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones
Annual Report to Security Holders
Chairman Thomas G. Wiggans Announces Retirement from Board
Investor Presentation
Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026
Material Contracts, Other Events
Reports Third Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
Financial Results, Press Release
Q1
FY 2025
Q3
Q2
FY 2024
Registration Statement for Securities to be Offered to Employees
S-3ASR
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Correspondence